Considerations To Know About XMU-MP-1
Kantarjian et al53 assessed the efficacy and safety of dasatinib, as compared with imatinib, for the very first-line therapy of CML-CP. Five hundred and nineteen sufferers with recently diagnosed CML-CP were randomly assigned to get dasatinib in a dose of one hundred mg once everyday (259 people) or imatinib at a dose of four hundred mg as soon as